Featured Publication Accessing Improved TB Medicines for Children Click here to download the full reportResearch Papers Treatment of Highly Drug-Resistant Pulmonary Tuberculosis Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialFor the PressPress Contact:Thomas Lynchp | +1 646 616 8639e | thomas.lynch@tballiance.org View the TB Alliance 2019 Annual Report
